Live
FierceBiotechAnalysts cut enGene cancer sales forecast after updated data widen gap to J&JBioPharma DiveFDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended10x Genomics News10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up - Zacks Investment ResearchEli LillyWill Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley FoolAbbottAbbott's Medical Device Strategy Supports Long-Term Growth Outlook - The Globe and MailFDA News ReleasesFDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and BiologicsBioPharma DiveLilly, Gilead lead pharma’s M&A boomEndpoints News'Pharma, not really’: Top young AI talent shuns careers at big drugmakersBio-RadBio-Rad to Participate in Upcoming Investor Conferences - Business WirePharmaVoiceBiotech layoffs are easing, but is the worst over?Thermo FisherThermo Fisher’s New Cell Therapy Bioreactor And Bioprocess Hub Might Change The Case For Investing In TMO - simplywall.stEli LillyLilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site - BioSpace

Archive

Latest Oldest Clear
Total 517
Page 29 / 29
Query --